B. Riley Raises TG Therapeutics (NASDAQ:TGTX) Price Target to $34.00

TG Therapeutics (NASDAQ:TGTX) had its price target increased by B. Riley from $29.00 to $34.00 in a research note released on Wednesday morning, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. B. Riley also issued estimates for TG Therapeutics’ Q3 2024 earnings at $0.03 EPS, Q4 2024 earnings at $0.10 EPS, FY2024 earnings at $0.06 EPS, FY2025 earnings at $1.02 EPS, FY2026 earnings at $1.47 EPS, FY2027 earnings at $2.43 EPS and FY2028 earnings at $3.36 EPS.

A number of other equities research analysts also recently weighed in on TGTX. LADENBURG THALM/SH SH boosted their price target on TG Therapeutics from $39.00 to $40.00 and gave the company a buy rating in a report on Thursday, May 2nd. JPMorgan Chase & Co. reaffirmed an overweight rating and issued a $25.00 price objective on shares of TG Therapeutics in a research note on Thursday, April 18th. Finally, HC Wainwright reissued a buy rating and set a $49.00 target price on shares of TG Therapeutics in a research report on Tuesday. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $31.83.

TG Therapeutics Stock Down 0.6 %

Shares of NASDAQ:TGTX traded down $0.12 during trading on Wednesday, hitting $19.92. 3,379,406 shares of the company were exchanged, compared to its average volume of 3,674,650. The firm’s 50 day moving average price is $18.74 and its 200-day moving average price is $16.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.62 and a quick ratio of 2.84. TG Therapeutics has a 12-month low of $6.46 and a 12-month high of $23.12. The stock has a market capitalization of $3.08 billion, a P/E ratio of 86.61 and a beta of 2.23.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.08. The company had revenue of $73.47 million for the quarter, compared to analyst estimates of $65.92 million. TG Therapeutics had a net margin of 14.24% and a return on equity of 31.34%. The firm’s revenue for the quarter was up 357.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.34) earnings per share. On average, research analysts predict that TG Therapeutics will post -0.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On TG Therapeutics

Several large investors have recently added to or reduced their stakes in the business. State of New Jersey Common Pension Fund D purchased a new stake in TG Therapeutics in the second quarter worth $2,022,000. Headlands Technologies LLC purchased a new stake in TG Therapeutics during the 2nd quarter valued at about $124,000. Ashton Thomas Private Wealth LLC purchased a new stake in TG Therapeutics during the 2nd quarter valued at about $35,000. Strategic Financial Concepts LLC bought a new position in TG Therapeutics during the 2nd quarter valued at approximately $530,000. Finally, Los Angeles Capital Management LLC raised its position in shares of TG Therapeutics by 20.4% in the 2nd quarter. Los Angeles Capital Management LLC now owns 92,277 shares of the biopharmaceutical company’s stock worth $1,642,000 after acquiring an additional 15,661 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.